111 related articles for article (PubMed ID: 27179113)
1. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter.
Leon LG; Funel N; Peters GJ; Avan A; Vistoli F; Boggi U; Giovannetti E
Clin Cancer Res; 2016 May; 22(10):2594. PubMed ID: 27179113
[No Abstract] [Full Text] [Related]
2. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Vena F; Hartley JA; Hochhauser D
Clin Cancer Res; 2016 May; 22(10):2595. PubMed ID: 27179114
[No Abstract] [Full Text] [Related]
3. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Van Cutsem E; Hidalgo M; Canon JL; Macarulla T; Bazin I; Poddubskaya E; Manojlovic N; Radenkovic D; Verslype C; Raymond E; Cubillo A; Schueler A; Zhao C; Hammel P
Int J Cancer; 2018 Oct; 143(8):2053-2064. PubMed ID: 29756206
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
Srinivas NR
Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):373-382. PubMed ID: 29488172
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
6. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
[TBL] [Abstract][Full Text] [Related]
7. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
Scheible H; Kraetzer F; Marx A; Johne A; Wimmer E
Drug Metab Dispos; 2017 Feb; 45(2):174-182. PubMed ID: 27934635
[TBL] [Abstract][Full Text] [Related]
9. Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Sarris EG; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):395-400. PubMed ID: 23846936
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Saif MW
Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):8-9. PubMed ID: 24322903
[No Abstract] [Full Text] [Related]
11. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
12. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC; Davis AM; Chimiczewski P; O'Malley DM; Provencher D; Vergote I; Ghamande S; Birrer MJ
Gynecol Oncol; 2020 Feb; 156(2):301-307. PubMed ID: 31870556
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Naqi N; Ahmad S; Murad S; Khattak J
Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
[TBL] [Abstract][Full Text] [Related]
14. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F
Ann Oncol; 2016 Jun; 27(6):1123-1128. PubMed ID: 26961147
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Necchi A; Lo Vullo S; Raggi D; Perrone F; Giannatempo P; Calareso G; Togliardi E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Colecchia M; Busico A; Pennati M; Zaffaroni N; Mariani L; Salvioni R
Urol Oncol; 2018 Jan; 36(1):8.e1-8.e8. PubMed ID: 28911922
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
[TBL] [Abstract][Full Text] [Related]
18. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
von Richter O; Massimini G; Scheible H; Udvaros I; Johne A
Br J Clin Pharmacol; 2016 Dec; 82(6):1498-1508. PubMed ID: 27483391
[TBL] [Abstract][Full Text] [Related]
19. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
